ABSTRACT
Chronic liver disease is a rapidly growing cause of morbidity and mortality worldwide, and this increase is largely driven by steatotic liver disease (SLD) comprising metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and MASLD and increased alcohol intake (MetALD). Hepatic steatosis and fibrosis are highly heritable and genetic variation has also been associated with the risk of hepatocellular carcinoma (HCC) and hepatic decompensation. This review summarizes the state of the art of genetics and genomics in SLD, with particular emphasis on potential clinical utility. Variants in/near genes including PNPLA3, TM6SF2, and HSD17B13 have been associated with cirrhosis and HCC in both MASLD and ALD, while others such as those in GCKR, TRIB1, and GPAM have been consistently associated with greater risk of hepatic steatosis in MASLD with much weaker effects if any on cirrhosis and HCC. While data on MetALD genetics are limited, we believe that the genetic risk factors for liver steatosis, cirrhosis, and HCC will be similar in MetALD compared to MASLD and ALD based on the largely shared genetic risk factors for MASLD and ALD. Finally, we discuss future directions in SLD genetics, notably genetically-defined disease subtypes, gene-environment interactions and their implications for therapy, and the utility of genetics in clinical risk stratification. Genetic studies have provided insight into important disease processes in SLD and may have an upcoming role in clinical care.
-
Keywords: SNP; Prognosis; Treatment response; Gene therapy
INTRODUCTION
Steatotic liver disease (SLD)—predominantly comprising metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-related liver disease (ALD)—is the greatest challenge facing gastro-hepatologists worldwide. SLD is becoming increasingly common in parallel with the high prevalence of obesity, diabetes, metabolic syndrome, and harmful alcohol use [
1-
4]. SLD is rapidly becoming the leading indication for liver transplantation and the predominant driver of hepatocellular carcinoma (HCC) in high-income countries, even in the absence of cirrhosis [
5-
7]. Yet, the majority of individuals with SLD will not experience major adverse liver events [
8]. The development of SLD is strongly shaped by inherited genetic variation, and there is substantial overlap in the genetic drivers across the spectrum of SLD. Genetics and genomics therefore offer important opportunities to understand disease pathogenesis, stratify patients into risk subgroups, and identify novel therapeutic targets. Here, we review the evidence from genetic studies of MASLD, ALD, and MetALD and the implications of these findings.
METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Common germline polymorphisms account for up to 30% of the observed inter-individual variability in liver fat content in MASLD [
9,
10]. This observation has been replicated across multiple genome-wide association studies (GWAS), twin [
10] and family studies [
11,
12]. The effect is greatest at the most severe end of the disease spectrum; having a first-degree relative with advanced MASLD fibrosis confers an 11.5 adjusted odds ratio for advanced fibrosis [
11]. This is distinct from monogenic disorders that are associated with severe phenotypes of MASLD (e.g., congenital lipodystrophies, severe insulin resistance syndromes) [
13].
Foundational genome wide association studies
Large GWAS have now identified dozens of independent genes or loci that are reproducibly associated with MASLD risk [
14-
16]. Genome-wide studies leveraging imaging, histology, and electronic health record–derived phenotypes have substantially refined understanding of the genetic architecture underlying MASLD. Early unbiased investigations, most notably from the Dallas Heart Study, identified a missense variant in PNPLA3 (p.Ile148Met) that was strongly associated with increased hepatic triglyceride content [
17]. There are substantial differences in allele frequency across ancestral groups (i.e., >40% in those of Hispanic ancestry, compared to <10% in those of African ancestry), which mirrors observed ancestral differences in MASLD prevalence and severity [
18], though there are many other factors that influence disparities [
19]. PNPLA3 encodes a lipid droplet–associated protein with a central role in hepatic lipid metabolism. Specifically, PNPLA3 interacts with ABHD5 to regulate triglyceride lipolysis by ATGL, which is a main hepatic lipase [
20-
22]. This mechanism appears to have a differential effect on long, polyunsaturated triglycerides compared to shorter, unsaturated triglycerides, which shifts the hepatocyte lipidome towards a more lipotoxic phenotype [
23,
24]. PNPLA3 has also emerged as a key genetic determinant of steatohepatitis, fibrosis, cirrhosis, and HCC [
25-
27]. In addition, notable geographic and ethnic differences have been observed in the distribution of the PNPLA3 rs738409 variant between Asian and Caucasian populations.
PNPLA3 rs738409 (G allele) is markedly more frequent in East Asian populations, with reported minor allele frequencies ranging from 35% to 45%, compared to approximately 20–25% in European ancestries [
28]. This may partially explain the relatively high prevalence of MASLD in Asia despite less severe metabolic conditions, commonly known as lean MASLD or lean patients with MASLD.
Lean patients with MASLD (body mass index [BMI]<23 kg/m
2) are common in Asians, and previous studies have demonstrated the role of
PNPLA3 genetic polymorphism has a greater impact on hepatic steatosis among lean individuals with MASLD than in overweight or obese group [
29]. In addition, another study from Taiwan showed that genetic variants in
PNPLA3 and
SAMM50 were linked with lean individuals with MASLD, and were replicated in the All of Us dataset, further supporting the important role of genetic susceptibility in the pathogenesis of lean MASLD [
30]. Overall, the major genetic risk factors for MASLD have been consistently validated across Asian cohorts [
31-
34]. Large-scale GWAS conducted in the Korean populations have identified several key MASLD-associated variants previously identified in Caucasian populations, including PNPLA3, APOB, GCKR, and APOC1. These findings suggest that the overall genetic architecture of MASLD in Asian populations largely mirrors the core susceptibility loci identified globally, underscoring their importance as potential targets for genetic risk stratification.
Subsequent large-scale meta-analyses of population-based cohorts identified additional MASLD-associated loci, including
GCKR and
TM6SF2, which have been replicated across diverse ancestral populations and diagnostic modalities including histology and imaging [
14,
35,
36].
TM6SF2 has been robustly associated with hard disease outcomes including HCC [
27,
37] while
GCKR variant associations with HCC and cirrhosis have been mixed [
25,
27]. In contrast, variants in
PPP1R3B, initially associated with reduced liver attenuation on imaging [
9], were subsequently shown to influence hepatic glycogen storage [
38] rather than triglyceride accumulation, underscoring the importance of careful phenotypic interpretation when using indirect measurements of SLD.
The establishment of large population biobanks has enabled further gains in statistical power and locus discovery. Exome-wide association studies identified variants in HSD17B13 that were associated with protection from liver disease, including reduced risk of steatohepatitis and fibrosis, despite in some contexts not being linked to changes in hepatic steatosis [
39-
41]. These protective effects were consistently replicated across histology-based cohorts, candidate gene studies, and multi-ancestry GWAS, supporting a role for HSD17B13 in modifying disease severity and progression rather than steatosis
per se [
42-
44]. HSD17B13 is a lipid droplet binding protein that may shift the intrahepatic lipid profile [
39,
45], though it is unclear precisely how this variant has such pervasively protective effects against advanced liver disease. Some possibilities include possibly affecting retinol metabolism [
46] but this mechanism is debated.
Imaging-based GWAS using magnetic resonance imaging (MRI)-PDFF (and derived liver fat from raw abdominal MRI data [
47,
48]) have identified additional loci, including
APOE [
49]. Phenome-wide association analyses on
APOE revealed certain alleles associated with increased hepatic steatosis and confer favorable cardiometabolic traits while protecting against Alzheimer’s disease, whilst others influenced only the presence of Alzheimer’s disease [
50]. Studies relying on diagnostic codes alone identified
PNPLA3, TM6SF2, GCKR, MTARC1, TRIB1, FTO, and
APOE [
51,
52]. Some associations, in particular FTO, may reflect effects on MASLD correlated traits such as abdominal adiposity rather than hepatic steatosis itself, or be a reflection of indirect effects (i.e., genetically encoded obesity [
53] subsequently associated with SLD). Though, aside from FTO (for obesity) and GCKR (for type 2 diabetes), the relative lack of overlap between GWAS-significant loci for body mass index, type 2 diabetes, and SLD [
36,
54,
55] is notable, which indicates that the genetic predictors of liver fat are distinct from additional environmental drivers of advanced SLD [
56], as discussed further below.
Whole-exome sequencing and gene-based burden testing have captured the effects of rarer variants. This approach has demonstrated predicted loss-of-function variants in CIDEB conferring protection against steatosis, steatohepatitis, and fibrosis [
57]. CIDEB is another fundamental hepatic lipid droplet-associated protein, and its loss seems to protect against MASLD through altered lipolysis with reduced insulin resistance [
58,
59].
Somatic mutations
CIDEB is one of several genes that accumulate somatic mutations in SLD. Deep sequencing from distinct locations within the same liver can identify recurrent somatic mutations within clonal populations [
60-
62]. These mutations give clones protection under MASLD promoting conditions through a variety of gene- and variant-specific mechanisms. For example, mutations on Serine-22 of
FOXO1 lead to persistent nuclear localization and increased gluconeogenesis, which appears to be beneficial in advanced MASLD. It is unclear to what extent this mutation contributes to these individuals’ systemic insulin resistance or whether it is a consequence of altered hepatic insulin signaling. Similarly, mutations in the DNA-binding domain of
TBX3 (predicted to cause protein destabilization) cause increased expression of genes that promote VLDL secretion from hepatocytes, thereby protecting them from elevated lipid load [
63]; in other genes (e.g.,
CIDEB and
GPAM) there are multiple different clones present within each patient.
In some cases, the mechanism of protection from somatic mutations is consistent with the germline function of the variant. For example, loss of function mutation in
CIDEB causes smaller lipid droplets, which is associated with increased lipolysis by adipose triglyceride lipase (encoded by
PNPLA2) and resulting upregulation of fatty acid oxidation pathways (i.e.,
PPARA) [
59]. However, for other genes work to date has shown counterintuitive mechanisms. Biallelic germline loss of function variants in
PKD1 leads to autosomal recessive polycystic kidney disease type 1, but variants near exon 15 are enriched in cirrhotic livers [
61]. In mouse models of MASLD, these variants protect against steatohepatitis through increased mTOR activation, prevention of glucose intolerance, and increased β-oxidation of fat, but it is unclear precisely how this happens [
61].
Somatic mutation analysis is a relatively recent field of liver genetics, and further affected genes are likely to be identified, though this technique generally requires carefully collected liver samples (snap-frozen cubes), costly deep sequencing, and substantial bioinformatic expertise to perform [
64]. While it initially appeared that only a minority of somatically mutated genes were also implicated in MASLD through germline variation [
65], larger sample sizes with greater coverage are demonstrating greater overlap [
57]. This principle could be applied in reverse by performing targeted somatic mutation sequencing in genes that have been previously implicated in MASLD GWAS. This appears to work in murine studies [
66] where a MASLD-inducing diet selected for loss-of-function clones in GPAM,
MBOAT7, PKD1, and
TBX3 [
63,
67,
68], Germline mutations and convergent somatic mutations are conceptually linked in that they both provide evidence of evolutionary benefit (at least at the cellular level) for these mutations, so this overlap in germline and somatically mutated genes provides intriguing biologic insights.
Integrative analyses
Integrative analyses combining imaging-derived phenotypes with diagnostic codes have further increased discovery power [
69]. These studies, as well as those taking a disease agnostic approach [
25,
26,
47,
70,
71], have demonstrated that common variants in
HFE, SERPINA1, and
ADH1B are primarily associated with hepatic fibrosis with an additional bystander effect on hepatic lipid content [
25,
26]. Analyses across SLD have also helped to identify causal genes, most notably
MBOAT7, which was initially identified in an ALD GWAS [
72] and subsequently replicated in MASLD [
67,
73].
MBOAT7 is a further example of a gene that perturbs the hepatic lipid profile towards a more lipotoxic context, as well as having modest effects on total lipid accumulation [
24,
66,
74,
75].
Large meta-analyses integrating imaging data, electronic health records, and multi-ethnic cohorts have now defined a core set of reproducible SLD-associated loci (
Table 1). Collectively, these implicate pathways governing hepatic lipid input and export, glucose metabolism, adiposity and fat distribution, insulin resistance, and mitochondrial and endoplasmic reticulum function. Studies using alanine aminotransferase (ALT) as a proxy phenotype have enabled even larger sample sizes [
14,
76] but show limited overlap with steatosis-specific loci, suggesting that ALT reflects broader mechanisms of hepatic injury beyond fat accumulation alone. Similarly, genetically informed case definitions based on clinical risk scores have identified additional loci (e.g.,
MAST3, an abdominal obesity gene) [
77], though these approaches have captured genes related to obesity [
78] and metabolic comorbidity as they have not been replicated in other histologically characterized cohorts [
35].
In contrast to steatosis, the genetic determinants of histologically defined steatohepatitis and fibrosis remain less well characterized, largely due to limited cohort sizes and reduced statistical power. Some early analyses that identified suggestive signals associated with disease activity, fibrosis, and lobular inflammation have not been replicated [
79]. Subsequent studies confirmed associations between PNPLA3 and histological features of steatohepatitis and fibrosis [
35,
51,
80]. Overall, almost all variants that have been independently replicated to associate with histological MASLD severity (steatohepatitis and/or fibrosis) also affect hepatic lipid content, though the reverse is not necessarily true (
Table 1). The only exceptions are those described above (e.g.,
HFE, SERPINA1, ADH1B) that exacerbate the severity of existing MASLD. It is interesting to observe that, even though inflammation is critical to the development of liver fibrosis, inflammatory pathways have not been consistently associated with liver fibrosis/cirrhosis in genetic association studies [
25]. Another limitation is that there are to our knowledge no GWAS specifically for MASLD-associated HCC.
To overcome the constraints of biopsy-based studies, imaging-derived biomarkers have increasingly been used as surrogate phenotypes. GWAS of corrected T1 time (cT1), an MRI-based measure of hepatic fibroinflammation [
81], identified associations at
PNPLA3, TM6SF2, and genes involved in metal transport (
SLC39A8) [
49]. However, some of these signals likely reflect the sensitivity of MRI to non-fibrotic processes, such as hepatic manganese accumulation [
82]. Nevertheless, as liver biopsy becomes less common in routine practice, the continued expansion of imaging-based cohorts represents a pragmatic strategy for advancing understanding of the genetics of steatohepatitis and fibrosis. Such studies will also be required to facilitate larger GWAS in children [
83].
ALCOHOL-RELATED LIVER DISEASE
The global prevalence of harmful alcohol use continues to rise, with ALD accounting for approximately 25% of global cirrhosis deaths and up to 20% of HCC cases [
84]. Although excessive alcohol consumption is the primary driver of ALD, only a subset of individuals progress from non-cirrhotic stages ranging from steatosis and steatohepatitis to advanced fibrosis, cirrhosis, and HCC, underscoring that other factors such as genetic variation are critical modulators of hepatic susceptibility [
85]. Growing evidence highlights a critical role for genetic and genomic factors in modulating disease risk, severity, and progression across the ALD spectrum [
86,
87]. Thus, understanding the genetic and genomic architecture underlying ALD pathogenesis is essential to explain heterogeneity in clinical outcomes, refine risk stratification for cirrhosis and HCC, and ultimately inform precision-based prevention and therapeutic strategies.
We highlight one key difference in the literature on ALD vs. MASLD genetics. In MASLD, most studies have focused on the early phenotype of hepatic steatosis and only subsequently assessed the impact of steatosis-associated variants on later phenotypes of cirrhosis and its complications. In contrast, most ALD GWAS have investigated advanced stage disease, specifically the presence versus absence of the definitive endpoints of cirrhosis or HCC among individuals with heavy alcohol consumption [
71,
72,
88,
89].
FOUNDATIONAL GENETIC DRIVERS OF CIRRHOSIS IN ALD
Large candidate-gene and GWAS have consistently demonstrated that common risk variants—most notably in
PNPLA3, TM6SF2, MBOAT7, and
HSD17B13—substantially modify susceptibility to advanced fibrosis and cirrhosis in heavy drinkers, despite comparable levels of alcohol exposure [
72,
85,
88]. In 2011, Stickel et al. [
90] evaluated the impact of
PNPLA3 rs738409 in ALD population from German cohorts, including 1,043 heavy alcohol users with or without liver injury and 376 at-risk drinkers from a population-based cohort. They demonstrated that PNPLA3 rs738409 G allele was more frequent in alcohol-associated cirrhosis and lowest in drinkers with steatosis with normal liver enzyme levels (35% vs. 17.7%) [
90]. The population attributable risk of cirrhosis among heavy alcohol users of allele PNPLA3 rs738409(G) was estimated at 26.6% [
90]. Subsequently, a landmark 2015 two-stage GWAS by Buch et al. [
72] evaluated genetic susceptibility to alcohol-associated cirrhosis by comparing heavy alcohol users with cirrhosis to alcohol-misusing controls without liver disease across multiple European cohorts. The discovery phase included 712 cases and 1,426 controls, followed by replication in German and Belgian cohorts, identifying genome-wide significant associations at
PNPLA3, TM6SF2, and
MBOAT7 loci [
72]. Key differences between these studies and earlier MASLD-focused GWAS included that these studies used individuals with excess alcohol intake without liver disease (or without advanced liver disease) as controls, thereby isolating genetic determinants of disease progression rather than alcohol consumption itself. Similar to MASLD, the findings showed that dysregulated lipid turnover is a shared pathogenic mechanism linking alcohol-associated cirrhosis and metabolic liver disease. In 2020, Innes et al. [
91] conducted a large GWAS study to identify genetic modifiers of susceptibility to alcohol-associated cirrhosis by comparing individuals with alcohol-related cirrhosis to heavy drinkers without liver disease. In addition to confirming previously established risk loci such as
PNPLA3, the study expanded this landscape by identifying two novel genome-wide significant associations: a missense variant in
MARC1 (rs2642438), in which the minor A allele conferred protection against alcohol-related cirrhosis, and an intronic variant near
HNRNPUL1 (rs15052), where the minor C allele increased cirrhosis risk [
91]. Notably, the protective MARC1 variant was also associated with lower liver fat and reduced hepatic injury markers, suggesting a functional role in mitochondrial metabolism and oxidative stress pathways and has been associated with MASLD [
91].
More recently, Schwantes-An et al. [
88] developed and validated a novel 20-SNP polygenic risk score PRS
ALC for alcohol-associated cirrhosis using a multi-stage, data-driven approach that meta-analyzed GWAS data and validated findings in two independent cohorts (UK Biobank and Indiana Biobank Liver cohort) totaling over 20,000 participants. The study found that individuals in the top decile of the PRS
ALC carried a nearly three- to four-fold higher risk of cirrhosis compared to those in the bottom decile, even after adjusting for clinical variables such as age, sex, body mass index, and diabetes [
88]. Crucially, the PRS
ALC provided incremental predictive accuracy over standard clinical risk factors and demonstrated significant utility in identifying “fast progressors” who developed severe liver dysfunction despite reporting lower behavioral alcohol intake. This research expands upon previous 3-SNP genetic scores (which included PNPLA3, HSD17B13, and TM6SF2) [
92] by identifying additional contributors like
KLHL8 and
PDE7B, while further underscoring the shared genetic architecture of liver injury by showing the PRS also effectively stratifies risk for cirrhosis [
88]. It should be noted that previous studies consistently reported genetic polymorphisms of ALDH1B and ALDH2 which are common in East Asian populations (40–50% carry the low activity of ALDH2) that causes toxic acetaldehyde and increase risk of ALD despite lower overall alcohol consumption [
93,
94].
GENETIC MODIFIERS OF PROGRESSION TO HCC IN ALD
Several studies have also identified variants that specifically predispose alcohol-associated cirrhotic patients to HCC. A 2014 individual participant meta-analysis of 2,503 patients identified associations between
PNPLA3 rs738409-G and ALD-associated HCC [
95]. Shortly after, another multicenter case-control design from liver centers across Europe (Switzerland, United Kingdom, Germany) that included patients with alcohol-associated cirrhosis with and without HCC investigated effects of
PNPLA3 and
TM6SF2 genotypes on HCC risk [
89]. The investigators demonstrated that the
PNPLA3 rs738409 G allele and the
TM6SF2 rs58542926 T allele were independently associated with about two-fold increased risk of HCC, even after adjustment for age, sex, diabetes, and body mass index, and accounting for nearly 50% of the combined population-attributable fraction for HCC [
89]. Importantly, by using controls with ALD cirrhosis, this study showed that these variants conferred HCC risk beyond their established effects on fibrosis/cirrhosis, suggesting a more direct role in hepatocarcinogenesis. The findings of this study established a genetic basis for interindividual variability in HCC risk among heavy drinkers and supported the concept that PNPLA3 and TM6SF2 contribute not only to disease progression but also to cancer susceptibility, laying the groundwork for genetically informed HCC risk stratification in ALD. Two other studies confirmed the
HSD17B13 rs72613567:TA splice variant as protective from HCC among individuals with ALD cirrhosis [
96,
97].
In 2022, Trépo et al. [
98] published a GWAS specifically focused on alcohol-related HCC, utilizing a two-stage case-control design that included over 4,000 European patients. The meta-analysis identified a novel susceptibility locus on chromosome 1 spanning the
WNT3A-WNT9A genes (rs708113) and confirmed the genome-wide significance of previously reported risk variants in
TM6SF2 and
PNPLA3 [
98]. A major breakthrough of this research compared to earlier candidate gene studies was the discovery that the
WNT3A-WNT9A variant modulates HCC risk independently of liver fibrosis severity, suggesting a distinct biological role in the Wnt/β-catenin signaling pathway during alcohol-mediated hepatocarcinogenesis [
98]. Somatic activation of the Wnt/β-catenin pathway, predominantly through gain-of-function CTNNB1 mutations, represents one of the most frequent oncogenic events in HCC [
99]—occurring in approximately 28% of cases and particularly enriched in alcohol-related tumors [
100]. Further study by Buch et al. [
72] utilizing large multicentre two-stage GWAS investigated host genetic determinants of HCC specifically among patients with alcohol-related cirrhosis by comparing 1,214 cirrhotic patients with HCC to 1,866 cirrhotic controls without HCC across European cohorts, with additional validation in individuals with alcohol misuse but no liver disease [
71]. The study confirmed previously established associations between
PNPLA3 (rs738409) and
TM6SF2 (rs58542926) variants and nearly two-fold increased HCC risk and identified a novel genome- wide significant association at the
TERT locus, where the rs2242652 A allele conferred a substantial protective effect against HCC development independent of age, sex, obesity, and diabetes. Importantly, the
TERT variant was not associated with the risk of developing cirrhosis itself, indicating a specific role in hepatocarcinogenesis rather than fibrosis progression [
71]. These associations align with the extensive literature on the importance of somatic mutations in TERT promoter and Wnt/β-catenin pathways seen in HCC; notably, there are no GWAS to our knowledge associating germline
TERT or
WNT3A-WNT9A variants to MASLD-associated HCC though somatic mutations in both have been observed in MASLD-associated HCC [
101,
102].
Compared with most of the MASLD literature, the ALD genetics field has largely been more consistent about using as controls individuals with excess alcohol intake but without cirrhosis or HCC. This may reduce statistical power to identify ALD-HCC cases, for instance if alcohol intake status is unknown or underreported. However, it allows for measurement of more direct effects of genetic variants on fibrosis (for the cirrhosis outcome) or hepatocarcinogenesis (for HCC outcomes) compared to studies that use the general population as controls, where effects of genetic variants on cirrhosis/HCC may be mediated by their effects on steatosis and fibrosis.
SHARED GENETIC MECHANISM ACROSS THE SLD SPECTRUM: IMPLICATIONS FOR METALD
The introduction of MetALD into the SLD nomenclature acknowledges the clinical reality where metabolic dysfunction and alcohol consumption synergistically drive liver injury [
103]. Most studies found that MASLD and ALD share largely similar genetic variants, which lead to liver cirrhosis. Schwantes-An et al. [
88] showed that PRS
ALC for ALD cirrhosis can also stratify risk of MASLD-related cirrhosis in the same cohort, which suggests shared genetic etiologies between MASLD and ALD [
85,
104,
105]. In addition, a large-scale 2024 multi-ancestry meta-analysis of 12 cohorts, including 18,265 cirrhosis cases and nearly 1.8 million controls by Ghouse et al. [
25] identified and validated 14 genome-wide significant risk associations for cirrhosis, demonstrating that many risk variants are located near genes involved in hepatic lipid metabolism. A key highlight of the study is the extensive overlap in genetic susceptibility between ALD and MASLD. The authors found that major risk loci, including those in PNPLA3, TM6SF2, and MBOAT7, exert directionally concordant effects on cirrhosis risk regardless of the underlying etiology [
25]. This integrative approach underscores that the biological threshold for advanced liver fibrosis is determined by shared genetic factors that modulate the hepatic response to both metabolic and toxic environmental triggers.
Genetic research specifically dedicated to the MetALD category is in its early stages and we are not aware of GWAS specifically for MetALD. However, current evidence detailed in the prior paragraph suggests MetALD is likely governed by a genetic architecture shared with MASLD and ALD [
106]. Major fibrosis and HCC risk loci, including in
PNPLA3, TM6SF2, HSD17B13, and
MBOAT7, have been confirmed to exert directionally concordant effects on the risk of cirrhosis and HCC across the entire SLD spectrum [
88,
106,
107]. Additionally, the vast majority of patients in prior ALD GWAS had cardiometabolic risk factors, and some of them may have met criteria for MetALD depending on their specific alcohol consumption.
Characterizing the precise genomic landscape of MetALD remains methodologically challenging due to the dynamic nature of alcohol consumption, which often fluctuates significantly over time. Most existing genetic data rely on cross-sectional assessments of alcohol intake, which are highly susceptible to self-reporting bias and can lead to the frequent misclassification of individuals with alcohol use disorder as pure MASLD cases [
108]. To improve the precision of genetic risk stratification in MetALD, research increasingly emphasizes the integration of longitudinal drinking histories and objective biomarkers like phosphatidylethanol (Peth) to delineate active versus historical consumption [
103,
109]. Furthermore, while large-scale “all-cause” cirrhosis studies identify shared genetic markers, they may obscure variants that interact uniquely with the specific moderate-to-heavy drinking thresholds that define the MetALD category [
26].
Future research using dedicated longitudinal MetALD cohorts, with alcohol exposure validated by Peth level as suggested from recent studies, together with multi-omics integration, is essential to understand how the polygenic background modulates the transition from simple steatosis to advanced cirrhosis in this heterogeneous population and to confirm the hypothesis of shared genetic polymorphism between MetALD and MASLD/ALD [
110,
111].
Future directions in SLD genetics
Molecular subtyping
Not all genetic variants associated with SLD work by the same mechanisms. One recent GWAS of MASLD identified 17 variants associated with MASLD and identified several categories of variants with distinct effects on other traits [
36]. Some including those in
PNPLA3, TM6SF2, APOE, MBOAT7, and
MARC1 were also associated with cirrhosis, while most other variants were not. There were also different patterns of effects on lipids, with some including those in
PNPLA3, TM6SF2, and
APOE associated with reduced atherogenic lipids and myocardial infarction, while others including those in
GCKR, TRIB1, MARC1, and
TOR1B were associated with increased low-density lipoprotein and myocardial infarction. While most variants increased risk of diabetes, the MASLD-promoting
GCKR and
TRIB1 variants were associated with decreased diabetes risk [
36]. Another study that identified 27 novel SLD-associated risk variants categorized the variants based on effects on plasma triglycerides as a proxy for hepatic retention of lipids [
114]; that is, variants that reduced plasma triglycerides presumably led to retention of these lipids inside the liver, while those that increased plasma triglycerides presumably had primarily extrahepatic effects (e.g., adipocyte lipid mobilization or
de novo lipogenesis) and secondarily hepatic effects. They found that while both variants that reduced plasma lipids vs. increased plasma lipids were associated with higher risk of cirrhosis and HCC, these effects were more pronounced in the reduced plasma lipid (hepatic lipid retention) group. In contrast, variants associated with increased plasma triglycerides were associated with higher risk of cardiovascular complications while the opposite was seen in variants associated with decreased plasma triglycerides [
16]. A third GWAS categorized variants as increasing
de novo lipogenesis (mostly corresponding to the increased plasma triglyceride group) vs. reducing hepatic fat export (corresponding to the decreased plasma triglyceride group) and found similar associations in which the
de novo lipogenesis variants tended to increase cardiovascular disease while the reduced hepatic fat export group reduced cardiovascular risk but had stronger effects on advanced liver disease [
15].
The findings that not all genetic variants drive liver disease by the same mechanism imply that different patients may have different underlying pathophysiology. For example, one recent study on subtypes of MASLD based on homeostatic model of insulin resistance scores vs. overall genetic risk identified “metabolic” contributions to MASLD dominated by substrate surplus largely related to systemic insulin resistance and excess caloric intake, vs. “genetic” contributions related to liver-specific mitochondrial redox state (
Fig. 1) [
112]. Notably, the genetic variants included in this study were those that primarily drive hepatic steatosis by reducing lipid export from the liver and which also increase liver fibrosis/cirrhosis [
37], so that the metabolic vs. genetic subtypes of MASLD may reflect the biology of a subset of genetic risk variants rather than global genetic contribution. Still, this concept raises the possibility that determining which mechanisms are dominant in which patients—whether based on genotyping, clinical phenotypes (e.g., diabetes status, lipid levels), or high-throughput methods such as metabolomics and proteomics—may help guide optimal therapy. There is limited and mostly retrospective or post-hoc evidence that
PNPLA3 genotype may influence response to therapy [
113-
115]. While some of the associations may simply reflect severity of disease (i.e., those with more advanced baseline disease are more likely to respond to therapy), mechanism may also play some role. For instance, omega-3 polyunsaturated fatty acids may be less likely to result in hepatic steatosis reduction in patients carrying
PNPLA3 risk variants [
116-
118].
PNPLA3 variant carriers typically have increased hepatic polyunsaturated fatty acids levels at baseline because one of the functions of wild-type
PNPLA3 is to mobilize polyunsaturated fatty acids so they can leave the liver [
119], and thus it is unlikely that PUFA supplementation would improve liver disease in these individuals. It could potentially be more beneficial in patients with MASLD driven by different disease biology however.
Gene-environment interactions
Genetics increase risk of disease but this effect is exacerbated by non-genetic environmental factors; a hypothetical example is shown in
Figure 2A. In one study of individuals without overt diabetes, the prevalence of MASLD increased based on
PNPLA3 genotype in individuals at the lowest quartile of insulin level (23% in CC vs. 39% in GG) but increased even more drastically in those with the highest quartile of insulin (54% vs. 94% in CC vs. GG) [
120]. Indeed, insulin resistance appeared to mediate interactions between MASLD,
PNPLA3 genotype, and other environmental factors including body mass index and triglyceride levels [
120]. These findings highlight the central role of insulin resistance in driving
PNPLA3-associated liver disease and imply that therapeutics aimed at reducing insulin resistance may attenuate genetic risk for hepatic steatosis. Indeed, later studies have found that diabetes interacts with
PNPLA3 genotype to multiplicatively increase risk of not just hepatic steatosis, but also major adverse liver outcomes (
Fig. 2B) [
121]. Moreover, several genetic variants may also influence adipose tissue by modulating insulin signaling and fat distribution which promotes MASLD progression [
122-
125]. One study reported the interaction between the
FTO (fat mass and obesity-associated) rs9939609 genotype and a high-calorie diet in adults with overweight [
126]. In addition, a recent study from Mongolia found that the
FTO rs9939609 AT/AA genotype, which promotes hepatic lipid accumulation and insulin resistance, was linked to MASLD [
123]. Furthermore, genetic variants in INSR (insulin receptor) gene and a key downstream signaling molecule such as
IRS1 (insulin receptor substrate 1) have been strongly associated with impairment in insulin’s ability to suppress lipolysis in adipose tissue [
124]. This impairment results in dysregulated lipolysis and altered fat distribution, effectively lowering the threshold at which environmental factors, including high-calorie diet, trigger the progression from simple steatosis to MASH [
125].
Other studies have found interactions between lifestyle factors and genetics to drive disease risk. In one study of MRI-quantified liver fat content in UK Biobank, liver fat content and iron-cT1 (a marker of hepatic fibrosis and inflammation) were increased with genetic risk (
PNPLA3 and
TM6SF2 risk variants and a polygenic risk score) and specific dietary patterns (Mediterranean-style diet, increased fruit/vegetable/legume intake, increased fish intake, and low red/processed meat intake) [
127]. The dietary and genetic factors also interacted to promote disease risk. For example, higher fruit/vegetable/legume intake was associated with a –0.35% reduction in liver fat content in
PNPLA3-rs738409-CC, but a –1.12% reduction in liver fat content in rs738409-GG carriers, implying that dietary effects could have as much as three-fold increased effect in those with high genetic risk and implying that these individuals may derive even greater benefit from lifestyle changes than those at lower genetic risk [
127]. Gene-diet interactions have also been associated with risk of hard endpoints. In one study in the National Health and Nutrition Examination Survey III,
PNPLA3 genotype also consistently interacted with modest alcohol intake, smoking, increased saturated fat intake, and increased cholesterol intake to increase risk of liver-related mortality [
128]. Finally, of particular relevance to ALD and MetALD are the well-documented gene-environment interactions between alcohol consumption and liver-related phenotypes. One study from the NHANES dataset found that even light alcohol use (≤7/14 drinks/week in women/men) was associated with increased liver-related mortality and that this effect was greater in
PNPLA3 risk allele carriers [
128]. Alcohol use can interact with both cardiometabolic risk factors and genetics. Another study using UK Biobank found that obesity and excess alcohol use (≥25/36 drinks/week in women/men) synergistically interacted with
PNPLA3 genotype [
129]. For example, the hazard ratio for liver-related death with excess alcohol use in those without obesity was 2.93 vs. 6.67 in
PNPLA3-rs738409-CC vs. -GG; HR with obesity without excess alcohol use was 1.73 vs. 6.85; and HR with excess alcohol use and obesity was 4.85 vs. 21.82 [
129]. These findings imply that efforts at reducing alcohol intake, achieving weight loss, and improving diet may be even more impactful in individuals at higher baseline risk due to their genetics. As a practical matter, knowing baseline genetic risk may be a motivating factor to help patients at increased risk adhere to lifestyle recommendations [
130].
Clinical risk stratification
To facilitate incorporation of genetics into clinical care, it will be critical to show that including genetics provides incremental value beyond standard of care, i.e., non-invasive tests (NITs) and/or liver biopsy in the context of risk stratification (
Fig. 3). There have been conflicting results in this space. One study of 197,509 participants in UK Biobank with SLD risk factors (increased waist circumference, increased BMI, excess alcohol intake, or type 2 diabetes) assessed prognostic accuracy of non-proprietary blood-based NITs, with or without a cirrhosis PRS, to predict 10-year risk of liver-related events [
131]. The best NITs including those most widely used in clinical practice—APRI, NFS, and FIB4—had area under the receiver operating characteristic curve values of approximately 0.8, and addition of the PRS did not increase prognostic accuracy [
131]. In another UK Biobank study, a PRS including
PNPLA3, TM6SF2, GCKR, and
MBOAT7 genotypes was not associated with cirrhosis and HCC among patients with low NFS, FIB4, or APRI [
132]. However, in patients with intermediate/high NIT values, or with other risk factors including diabetes or obesity, the PRS was associated with risk of cirrhosis and HCC [
132]. Another study assessed the prognostic value of genetics in individuals with ALT elevations and likely MASLD in two independent cohorts, Michigan Genomics Initiative and UK Biobank [
133]. In low FIB4 participants, there was again little association between a cirrhosis PRS or
PNPLA3 genotype and incident cirrhosis; but in intermediate/high FIB4 participants, both the PRS and
PNPLA3 genotypes were significantly associated with incident disease. Further, participants with intermediate FIB4 who had both high-risk genetics (
PNPLA3-rs738409-GG homozygosity) and clinical risk factors (diabetes) had risk for incident cirrhosis similar to that of those with high FIB4 [
133], so that they were “bumped up” a risk category. Another study assessing fibrosis stage using magnetic resonance elastography or VCTE found that patients with diabetes and low FIB4 but elevated genetic risk had a prevalence of advanced fibrosis comparable to that of the overall intermediate FIB4 population with diabetes [
134]. Finally, a study of almost 100,000 Million Veterans Program participants assessed FIB4 slope (change in FIB4 values divided by time elapsed, among those with serial measurements) as a surrogate measure of disease progression, and found that the
PNPLA3 and
TM6SF2 risk loci associated with MASLD were associated with greater FIB4 slope [
135]. Together, these studies imply that even if genetics do not improve prognostic area under the curve—which is intrinsically a continuous measure—when used in conjunction with clinically-utilized thresholds for FIB4 and other NITs, genetics may provide additional prognostic information, especially when combined with cardiometabolic risk factors.
Genetics has also been shown to carry prognostic significance over histology. In 2,075 patients with biopsy-confirmed MASLD from the MASH Clinical Research Network,
PNPLA3-rs738409-G allele was associated with increased risk of LRE especially in conjunction with diabetes status [
121]. A separate study of 1,178 patients in Japan with biopsy-confirmed MASLD found a significant association between LRE and
PNPLA3 genotype as well as between LRE and a PRS including
PNPLA3, TM6SF2, and
HSD17B13 genotypes [
136]. Notably, both studies found that the absolute increase in LRE due to
PNPLA3 risk alleles was greater in participants with advanced fibrosis [
121,
136], similar to the NIT-based studies that also found that genetics showed stronger associations in those with high FIB4 scores. Together, these findings imply that genetic risk (either
PNPLA3 genotype or polygenic risk scores) combined with cardiometabolic risk factors (especially diabetes) may provide prognostic information beyond NITs and histology and result in actionable risk stratification (
Fig. 3). However, data in patients undergoing elastography (which is largely replacing biopsy for risk stratification) are still lacking and are crucial for wider expansion to clinical care.
There has been interest in using genetics to stratify risk of HCC in at-risk populations. However, despite the strong associations between several risk alleles and HCC compared to controls with cirrhosis, studies have yielded mixed results. One European study in ALD and hepatitis C-related cirrhosis found that polygenic risk scores including
PNPLA3, TM6SF2, HSD17B13, APOE, and
MBOAT7 variants were associated with risk of HCC in patients with cirrhosis [
137]. However, the incremental benefit of incorporating genetics on top of the aMAP score was minimal. Another US study showed that incorporating
PNPLA3 genotype improved prediction of one-year but not two-year HCC risk in patients with cirrhosis [
138].
Therapeutic implications
Drugs targeting genes and variants implicated in SLD are in development [
139]. ARO-PNPLA3 is a conjugated small interfering RNA targeted at
PNPLA3-rs738409G and resulted in >70% reduction of mutant
PNPLA3 expression and >20% relative reduction in liver fat content in phase 1 trials [
140]. AZD2693 is an anti-sense oligonucleotide also targeted against
PNPLA3-rs738409-G which also potentially decreased expression and liver fat reduction in phase 1 trials [
141]. However, in a phase 2b randomized controlled trial, AZD2693 did not show efficacy over placebo in reduction in steatohepatitis or fibrosis regression [
142]. Rapirosirin (formerly HSD-ALN) is a small interfering RNA agent which reduces HSD17B13 expression; a phase 2 clinical trial comparing rapirosirin to placebo is underway (NCT05519475) [
143]. A phase 2 trial for an antisense oligonucleotide inhibiting DGAT2 (ION224) also demonstrated efficacy in steatohepatitis reduction without worsening of fibrosis [
144].
Genetics may also influence response to non-targeted therapy, and this has been best studied for the
PNPLA3-rs738409-G genotype. However, studies on influence of
PNPLA3 genotype on treatment response have yielded conflicting results for glucagon-like peptide-1 receptor agonists and no association with resmetirom response [
113,
145-
147]. All studies on differential response to pharmacotherapy to date have been post-hoc, and prospective analyses are required to address this topic.
CONCLUSIONS
Genetic studies have provided insight into important disease processes in SLD. Variants associated with MASLD and ALD overlap almost completely for non-HCC phenotypes, with the caveat that data for MASLD-related HCC are minimal. The findings suggest that mechanisms underlying fibrosis and carcinogenesis may overlap. Future prospective studies may demonstrate utility of genetics including PNPLA3-rs738409-GG genotype and polygenic risk scores (if appropriate ancestry-specific calibration can be demonstrated) in routine clinical care. So far this concept has been best established in intermediate-high risk MASLD (by FIB4 and/or biopsy) and strong cardiometabolic risk factors (especially type 2 diabetes) for prediction of MALO; studies based on elastography-based disease staging remain largely lacking. Gene therapy targeted against PNPLA3 variants and HSD17B13 is in development but the PNPLA3 variant-targeting AZD2693 phase 2b clinical trial was negative for histologic outcomes and histologic efficacy for other agents has not been demonstrated.
FOOTNOTES
-
Authors’ contribution
JPM, KW, VP, and VLC: drafting of manuscript. ET, EKS: critical review of manuscript.
-
Acknowledgements
JPM was supported by Birmingham Health Partners and Action Medical Research grant GN4039. VLC was supported in part by K08 DK132312. EKS is supported by National Institutes of Health grants R01 DK131787, R01 DK128871, R01 DK141823, MBIOFar, and the University of Michigan Department of Internal Medicine.
-
Conflicts of Interest
The authors have no financial conflicts of interest relevant to this topic but disclose the following for transparency. JPM is a consultant for Eli Lilly, Novo Nordisk, and Inventiva. KW has received research grants from GlaxoSmithKline. ET has received research support and honoraria from Gilead. VLC has received grants from AstraZeneca, KOWA, and Ipsen. The Regents of the University of Michigan and EKS. have a pending patent on the use of systems and methods for analysis of samples associated with MASLD insulin resistance and related conditions.
Figure 1.Metabolic dysfunction-associated steatotic liver disease (MASLD) associated with increased genetic risk vs. systemic insulin resistance. MASLD associated with genetic risk (left side) is typically associated with increased risk of advanced liver disease including hepatocellular carcinoma but lower risk of coronary artery disease and dyslipidemia (note that this refers specifically to variants associated with both hepatic steatosis and liver fibrosis, most prototypically those in
PNPLA3 and
TM6SF2, as discussed in the text. It is not meant to imply that all genetic variants have these same effects). In contrast, MASLD associated with systemic insulin resistance (right side) is comparatively associated with increased risk of cardiovascular and cerebrovascular disease, hypertension, type 2 diabetes, chronic kidney disease, and extrahepatic malignancy. IR, insulin resistance; SNP, single nucleotide polymorphism. This presentation was created in BioRender. To access the original source of this presentation, visit:
https://app.biorender.com/illustrations/69a82e0e80ef8e61f9126bd8.
Figure 2.Gene-environment interactions. (A) Hypothetic depiction of gene-environment interactions. The y-axis represents prevalence of disease and x-axis represents genetic risk. The black line represents absence of an environmental (non-genetic) risk factor while the red line represents presence of the environmental risk factor. The difference in disease prevalence in individuals with vs. without the environmental risk factor is lowest in those with lowest genetic risk (delta 5%), then in those with intermediate genetic risk (delta 11%), and highest in the highest genetic risk group (delta 22%). (B) Interactions between genetic risk defined by number of PNPLA3-rs738409-G or TM6SF2-rs58542926-T alleles or value of a polygenic risk score, and environmental risk factors. ↑ implies that higher genetic risk multiplicatively interacts with a higher value of the environmental risk factor to increase risk of outcomes of interest, while ↓ implies that higher genetic risk interacts with a higher value of the environmental risk factor to decrease risk of clinical outcomes. This list is not exhaustive and we prioritized reporting “harder” outcomes such as liver-related death (LRD), hepatocellular carcinoma (HCC), or liver-related events (LRE) usually defined as HCC or hepatic decompensation and over hepatic cirrhosis/fibrosis, over hepatic steatosis.
Figure 3.Genetics in risk stratification in liver disease. (A) Genes in/near which alleles have been associated with disease progression in all steatotic liver disease (SLD) or specifically in alcohol-related liver disease (ALD). Variants are shown based on their effect on progression from steatosis to advanced fibrosis/cirrhosis, and from advanced fibrosis/cirrhosis to hepatocellular carcinoma. (B) Schematic of the impact of genetic risk factors for risk stratification in SLD. In patients with low or intermediate non-invasive tests (NITs) or histology, having both strong clinical risk factors (most notably diabetes) and increased genetic risk may result in a patient having similar risk of advanced disease as someone with intermediate or high NIT/histology results, respectively, and being reclassified accordingly. Genetic risk factors are best established for PNPLA3-rs738409-GG genotype or a high value of a polygenic risk score.
Table 1.Summary of key genes and phenotypes associated with steatotic liver disease
Table 1.
|
Implicated gene |
Variant/chromosome:position (hg38) |
Presumed mechanism |
MASLD steatosis |
ALD cirrhosis |
ALD HCC |
All-cause cirrhosis |
All-cause HCC |
|
MTARC1 (MARC1)
|
rs2642438-G |
Encodes a mitochondrial outer-membrane enzyme involved in reductive metabolism of N-oxygenated compounds, including nitric oxide and xenobiotics [148,149] |
↑[14,36,150] |
↓[91] |
↓[91] |
↓[25,69,151] |
|
|
chr1:220970028 |
|
WNT3A-WNT9A
|
rs708113-T |
Regulating the Wnt/β-catenin (canonical) signaling pathway involved in carcinogenesis [152] |
|
|
↑[71,98,153] |
|
|
|
chr1:227975444 |
|
GCKR
|
rs1260326-T |
Regulates hepatic glucokinase activity, coordinating glucose utilisation with down-stream lipid synthesis [154] |
↑[35,36,49,69,150] |
|
|
|
|
|
chr2:27730940 |
|
HSD17B13
|
rs72613567-TA |
Liver-enriched lipid droplet–associated protein implicated in hepatocellular lipid handling and retinol metabolism [46,155] |
↓(Steatohepatitis) [14,35,41] |
↓[41,96,97] |
↓[41,96,97] |
↓[14,35,41] |
↓[14,35,41] |
|
chr4:87310241 |
|
ADH1B
|
rs1229984-C |
Cytosolic enzyme responsible for ethanol metabolism in hepatocytes, particularly at low alcohol concentrations [156] |
|
↑[26] |
|
↑(Alcohol-related liver injury) [36,48] |
↑[26] |
|
chr4:100239319 |
|
MTTP
|
rs7661964-A |
Required for assembly and secretion of VLDL particles and chylomicrons, enabling hepatic triglyceride export [157] |
↑[36] |
|
|
|
↓[27] |
|
chr4:100505326 |
|
TERT
|
rs2242652-A |
Telomere length maintenance/Wnt signaling [158] |
|
|
↓[71] |
|
↓[27] |
|
chr5:1288011 |
|
FAF2
|
rs374702773-G |
Lipid droplet stabilization [159] |
↓[70] |
|
|
|
|
|
chr5:176501480 |
|
TRIB1
|
rs112875651-G |
Influences hepatic de novo lipogenesis and VLDL production [160] |
↑[14,36,150] |
|
|
|
|
|
chr8:126506694 |
|
GPAM
|
rs4918722-C |
Catalyses the first committed step in triglyceride and phospholipid synthesis [161] |
↑[36,69] |
|
|
|
|
|
chr10:113947040 |
|
SERPINA1
|
rs28929474-T |
Encodes α-1 antitrypsin; mutation results in toxic accumulation of misfolded protein [162] |
|
|
|
↑[14,26,70,163] |
|
|
chr14:94844947 |
|
HNRNPUL1
|
rs15052-C |
Transcription regulation/TGFB1 modulation involves in fibrosis [91] |
|
↑[91] |
|
|
|
|
chr19:41249781 |
|
TM6SF2
|
rs58542926-T |
Regulates VLDL secretion, influencing hepatic triglyceride retention and lipotoxicity [164] |
↑[36,72,150,165] |
↑[72,89,91] |
↑[98] |
↑[36,72,150,165] |
↑[27] |
|
chr19:19379549 |
|
APOE
|
rs429358-T |
Key component of hepatic lipoprotein transport [166] |
↑[25,26,36,47,50,150] |
|
|
↑[25,26,36,47,50,150] |
↑[27] |
|
chr19:45411941 |
|
MBOAT7
|
rs626283-C |
MBOAT7 remodels phospholipids and modulates inflammatory responses [66] |
↑[36,67,72,73] |
|
|
↑[72,89] |
↑[67,72,73] |
|
chr19:54677001 |
|
PNPLA3
|
rs738409-G |
Lipid droplet–associated protein that regulates hepatic lipase activity [20] |
↑[26,35,36] |
↑[72,88-91,167] |
↑[98,168] |
↑[26,35,36] |
↑[26,35,36] |
|
chr22:44324730 |
Abbreviations
alcohol-related liver disease
genome-wide association studies
metabolic dysfunction–associated steatotic liver disease
MASLD and increased alcohol intake
REFERENCES
- 1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet 2024;403:1027-1050.
- 2. Hu M, Le MH, Yeo YH, Wijarnpreecha K, Likhitsup A, Kim D, et al. Diabetes prevalence and management patterns in US adults, 2001-2023. Acta Diabetol 2025;62:2159-2170.
- 3. Chew NWS, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab 2023;35:414-428.e3.
- 4. Esser MB, Sherk A, Liu Y, Naimi TS. Deaths from excessive alcohol use - United States, 2016-2021. MMWR Morb Mortal Wkly Rep 2024;73:154-161.
- 5. Koh JH, Ng CH, Nah B, Tan DJH, Loomba R, Huang DQ. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2024;22:197-199.e3.
- 6. Younossi ZM, Stepanova M, Al Shabeeb R, Eberly KE, Shah D, Nguyen V, et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun 2024;8:e0352.
- 7. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. Bmj 2018;362:k2817.
- 8. Ochoa-Allemant P, Hubbard RA, Kaplan DE, Serper M. Cause-specific mortality in patients with steatotic liver disease in the United States. J Hepatol 2025;83:860-869.
- 9. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
- 10. Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 2015;149:1784-1793.
- 11. Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, et al. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest 2022;132:e162513.
- 12. Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127:2697-2704.
- 13. Mann JP, Savage DB. What lipodystrophies teach us about the metabolic syndrome. J Clin Invest 2019;129:4009-4021.
- 14. Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, et al. A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat Genet 2022;54:761-771.
- 15. Ahmed A, Cule M, Bell JD, Sattar N, Yaghootkar H. Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer. J Hepatol 2024;81:921-929.
- 16. Jamialahmadi O, De Vincentis A, Tavaglione F, Malvestiti F, Li-Gao R, Mancina RM, et al. Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 2024;30:3614-3623.
- 17. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
- 18. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
- 19. Samala N, Xin Y, Wilson LA, Yates K, Loomba R, Hoofnagle JH, et al. Non-Hispanic black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype. Am J Gastroenterol 2024;119:1857-1865.
- 20. Yang A, Mottillo EP, Mladenovic-Lucas L, Zhou L, Granneman JG. Dynamic interactions of ABHD5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. Nat Metab 2019;1:560-569.
- 21. Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem 2018;293:9232.
- 22. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010;285:6706-6715.
- 23. Luukkonen PK, Nick A, Hölttä-Vuori M, Thiele C, Isokuortti E, Lallukka-Brück S, et al. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight 2019;4:e127902.
- 24. Mann JP, Pietzner M, Wittemans LB, Rolfe EL, Kerrison ND, Imamura F, et al. Insights into genetic variants associated with NASH-fibrosis from metabolite profiling. Hum Mol Genet 2020;29:3451-3463.
- 25. Ghouse J, Sveinbjörnsson G, Vujkovic M, Seidelin AS, Gellert-Kristensen H, Ahlberg G, et al. Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis. Nat Genet 2024;56:827-837.
- 26. Vujkovic M, Kaplan DE, Ghouse J, Loza BL, Brancale J, Lewis A, et al. Germline variants influence chronic liver disease progression through distinct pathways. medRxiv. 2025.09.16.25335186 [Preprint]. 2025 [cited 2026 Jun 8]. Available from: https://doi.org/10.1101/2025.09.16.25335186.
- 27. Chinaka I, Schofield A, Amos CI, Roberts LR, Chen VL, Han Y, et al. Multi-ancestry genome-wide association meta-analysis of hepatocellular carcinoma identifies eight risk loci including MAP3K9, DHRS1, MTTP, and 8q24.21. HGG Adv 2026:100639.
- 28. Kozlitina J, Sookoian S. Global Epidemiological Impact of PNPLA3 I148M on Liver Disease. Liver Int 2025;45:e16123.
- 29. Lin H, Wong GL, Whatling C, Chan AW, Leung HH, Tse CH, et al. Association of genetic variations with NAFLD in lean individuals. Liver Int 2022;42:149-160.
- 30. Hsu SW, Lin MR, Chou WH, Wan YY, Kao WY, Chang WC. Cross-ancestry discovery of genetic risk variants for lean metabolic dysfunction-associated steatotic liver disease. Cell Biosci 2025;15:131.
- 31. Lai KH, Wong VW. Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management. Singapore Med J 2026 Apr 10. doi: 10.4103/singaporemedj.SMJ-2025-167.
- 32. Lee Y, Cho EJ, Choe EK, Kwak MS, Yang JI, Oh SW, et al. Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population. Sci Rep 2024;14:9753.
- 33. Chung GE, Lee Y, Yim JY, Choe EK, Kwak MS, Yang JI, et al. Genetic polymorphisms of PNPLA3 and SAMM50 are associated with nonalcoholic fatty liver disease in a Korean population. Gut Liver 2018;12:316-323.
- 34. Wang JJ, Chen XY, Zhang YR, Shen Y, Zhu ML, Zhang J, et al. Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease. Front Physiol 2025;16:1562848.
- 35. Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol 2020;73:505-515.
- 36. Chen Y, Du X, Kuppa A, Feitosa MF, Bielak LF, O’Connell JR, et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet 2023;55:1640-1650.
- 37. Kubina M, Prasitsumrit V, Tan J, Quek JWE, Peddu D, Mishra A, et al. Meta-analysis: effects of steatotic liver disease-associated genetic risk alleles on longitudinal outcomes. Aliment Pharmacol Ther 2025;62:244-276.
- 38. Kahali B, Chen Y, Feitosa MF, Bielak LF, O’Connell JR, Musani SK, et al. A noncoding variant near PPP1R3B promotes liver glycogen storage and MetS, but protects against myocardial infarction. J Clin Endocrinol Metab 2021;106:372-387.
- 39. Hudert CA, Adams LA, Alisi A, Anstee QM, Crudele A, Draijer LG, et al. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. Hepatol Commun 2022;6:1934-1948.
- 40. Gellert-Kristensen H, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. High risk of fatty liver disease amplifies the alanine transaminase-lowering effect of a HSD17B13 variant. Hepatology 2020;71:56-66.
- 41. Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 2018;378:1096-1106.
- 42. Ghouse J, Gellert-Kristensen H, O’Rourke CJ, Seidelin AS, Thorleifsson G, Sveinbjörnsson G, et al. Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development. JHEP Rep 2025;7:101485.
- 43. Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 2020;72:845-856.
- 44. Pirola CJ, Garaycoechea M, Flichman D, Arrese M, San Martino J, Gazzi C, et al. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. J Lipid Res 2019;60:176-185.
- 45. Luukkonen PK, Tukiainen T, Juuti A, Sammalkorpi H, Haridas PAN, Niemelä O, et al. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. JCI Insight 2020;5:e132158.
- 46. Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, et al. 17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease. Hepatology 2019;69:1504-1519.
- 47. Emdin CA, Haas M, Ajmera V, Simon TG, Homburger J, Neben C, et al. Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. Gastroenterology 2021;160:1620-1633.e13.
- 48. Haas ME, Pirruccello JP, Friedman SN, Wang M, Emdin CA, Ajmera VH, et al. Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom 2021;1:100066.
- 49. Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, et al. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 2020;73:241-251.
- 50. Palmer ND, Kahali B, Kuppa A, Chen Y, Du X, Feitosa MF, et al. Allele-specific variation at APOE increases nonalcoholic fatty liver disease and obesity but decreases risk of Alzheimer’s disease and myocardial infarction. Hum Mol Genet 2021;30:1443-1456.
- 51. Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway IB, et al. GWAS and enrichment analyses of nonalcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 2019;17:135.
- 52. Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of nonalcoholic fatty liver disease. Cell Rep Med 2021;2:100437.
- 53. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. Hum Mol Genet 2018;27:3641-3649.
- 54. Huerta-Chagoya A, Schroeder P, Mandla R, Li J, Morris L, Vora M, et al. Rare variant analyses in 51,256 type 2 diabetes cases and 370,487 controls reveal the pathogenicity spectrum of monogenic diabetes genes. Nat Genet 2024;56:2370-2379.
- 55. Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet 2019;28:166-174.
- 56. Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 2017;49:842-847.
- 57. Verweij N, Haas ME, Nielsen JB, Sosina OA, Kim M, Akbari P, et al. Germline mutations in CIDEB and protection against liver disease. N Engl J Med 2022;387:332-344.
- 58. Zheng J, Gaspar RC, Sakuma I, Hubbard BT, Zhang D, Nasiri A, et al. Cideb knockdown in mice increases mitochondrial fat oxidation and reverses hepatic steatosis and insulin resistance by the plasma membrane sn-1,2-DAGs-PKCε-insulin receptor kinase(T1150) pathway. Diabetologia 2025;68:2906-2920.
- 59. Zeng Q, Patel S, Wang X, Hsieh MH, Li Z, Ren X, et al. Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation. J Hepatol 2026;84:35-50.
- 60. Ng SWK, Rouhani FJ, Brunner SF, Brzozowska N, Aitken SJ, Yang M, et al. Convergent somatic mutations in metabolism genes in chronic liver disease. Nature 2021;598:473-478.
- 61. Zhu M, Wang Y, Lu T, Guo J, Li L, Hsieh MH, et al. PKD1 mutant clones within cirrhotic livers inhibit steatohepatitis without promoting cancer. Cell Metab 2024;36:1711-1725.e8.
- 62. Li R, Di L, Li J, Fan W, Liu Y, Guo W, et al. A body map of somatic mutagenesis in morphologically normal human tissues. Nature 2021;597:398-403.
- 63. Mannino G, Quinn G, Zhu M, Wang Z, Wang X, Li B, et al. Somatic mutations in TBX3 promote hepatic clonal expansion by accelerating VLDL secretion. J Clin Invest 2025;135:e191855.
- 64. Dou Y, Gold HD, Luquette LJ, Park PJ. Detecting somatic mutations in normal cells. Trends Genet 2018;34:545-557.
- 65. Mann JP, Hoare M. A minority of somatically mutated genes in pre-existing fatty liver disease have prognostic importance in the development of NAFLD. Liver Int 2022;42:1823-1835.
- 66. Wang Z, Zhu S, Jia Y, Wang Y, Kubota N, Fujiwara N, et al. Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease. Cell 2023;186:1968-1984.e20.
- 67. Teo K, Abeysekera KWM, Adams L, Aigner E, Anstee QM, Banales JM, et al. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J Hepatol 2021;74:20-30.
- 68. Mushi JM, Sharma PJ, Schofield A, Chen VL, Cordell HJ, Davies SP, et al. Genes that cause severe liver disease in children also influence risk and severity of common liver conditions in adults. medRxiv. 2025.05.09.25326407 [Preprint]. 2025 [cited 2026 Jun 8]. Available from: https://doi.org/10.1101/2025.05.09.25326407.
- 69. Sveinbjornsson G, Ulfarsson MO, Thorolfsdottir RB, Jonsson BA, Einarsson E, Gunnlaugsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet 2022;54:1652-1663.
- 70. Schwantes-An TH, Darlay R, Mathurin P, Masson S, Liangpunsakul S, Mueller S, et al. Genome-wide association study and meta-analysis on alcohol-associated liver cirrhosis identifies genetic risk factors. Hepatology 2021;73:1920-1931.
- 71. Buch S, Innes H, Lutz PL, Nischalke HD, Marquardt JU, Fischer J, et al. Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut 2023;72:381-391.
- 72. Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet 2015;47:1443-1448.
- 73. Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016;150:1219-1230.e6.
- 74. Luukkonen PK, Zhou Y, Hyötyläinen T, Leivonen M, Arola J, Orho-Melander M, et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 2016;65:1263-1265.
- 75. Helsley RN, Varadharajan V, Brown AL, Gromovsky AD, Schugar RC, Ramachandiran I, et al. Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease. Elife 2019;8:e49882.
- 76. Chen VL, Du X, Chen Y, Kuppa A, Handelman SK, Vohnoutka RB, et al. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun 2021;12:816.
- 77. Miao Z, Garske KM, Pan DZ, Koka A, Kaminska D, Männistö V, et al. Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease. HGG Adv 2022;3:100056.
- 78. Zhu Z, Guo Y, Shi H, Liu CL, Panganiban RA, Chung W, et al. Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol 2020;145:537-549.
- 79. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 2010;139:1567-1576. 1576.e1-6.
- 80. Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010;52:904-912.
- 81. Alkhouri N, Beyer C, Shumbayawonda E, Andersson A, Yale K, Rolph T, et al. Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH. J Hepatol 2025;82:438-445.
- 82. Seidelin AS, Nordestgaard BG, Tybjærg-Hansen A, Stender S. Does SLC39A8 Ala391Thr confer risk of chronic liver disease? Antioxid Redox Signal 2024;41:591-596.
- 83. Wattacheril J, Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, et al. Genome-wide associations related to hepatic histology in nonalcoholic fatty liver disease in Hispanic boys. J Pediatr 2017;190:100-107.e2.
- 84. Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol 2023;20:37-49.
- 85. Scott E, Anstee QM. Genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clin Med (Lond) 2018;18:s54-s59.
- 86. Gensluckner S, Schnefeld HL, Embacher J, Hansen CD, Balcar L, Bech KT, et al. PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis. JHEP Rep 2026;8:101649.
- 87. Wang Q, Wang Z, Hu M, Liu F, Wang Z. Genetic insights into alcohol-associated liver disease: integrative transcriptome-wide analysis identifies novel susceptibility genes. Front Med (Lausanne) 2025;12:1623367.
- 88. Schwantes-An TH, Whitfield JB, Aithal GP, Atkinson SR, Bataller R, Botwin G, et al. A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry. Hepatol Commun 2024;8:e0431.
- 89. Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. Am J Gastroenterol 2018;113:1475-1483.
- 90. Stickel F, Buch S, Lau K, Meyer zu Schwabedissen H, Berg T, Ridinger M, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011;53:86-95.
- 91. Innes H, Buch S, Hutchinson S, Guha IN, Morling JR, Barnes E, et al. Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1. Gastroenterology 2020;159:1276-1289.e7.
- 92. Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, et al. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol 2022;76:275-282.
- 93. Tadokoro T, Oura K, Nakahara M, Fujita K, Tani J, Morishita A, et al. Genetic polymorphisms of ALDH2 and ADH1B in alcohol-induced liver injury: molecular mechanisms of inflammation and disease progression in East Asian populations. Int J Mol Sci 2025;26:8328.
- 94. Wang Q, Chang B, Li X, Zou Z. Role of ALDH2 in hepatic disorders: gene polymorphism and disease pathogenesis. J Clin Transl Hepatol 2021;9:90-98.
- 95. Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, et al. Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 2014;59:2170-2177.
- 96. Yang J, Trépo E, Nahon P, Cao Q, Moreno C, Letouzé E, et al. A 17-beta-hydroxysteroid dehydrogenase 13 variant protects from hepatocellular carcinoma development in alcoholic liver disease. Hepatology 2019;70:231-240.
- 97. Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, et al. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers. Hepatology 2020;72:88-102.
- 98. Trépo E, Caruso S, Yang J, Imbeaud S, Couchy G, Bayard Q, et al. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncol 2022;23:161-171.
- 99. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44:694-698.
- 100. Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505-511.
- 101. Ki Kim S, Ueda Y, Hatano E, Kakiuchi N, Takeda H, Goto T, et al. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Int J Cancer 2016;139:2512-2518.
- 102. Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest 2022;132:e154515.
- 103. Arab JP, Díaz LA, Rehm J, Im G, Arrese M, Kamath PS, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol 2025;82:744-756.
- 104. Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol 2021;74:775-782.
- 105. Bianco C, Tavaglione F, Romeo S, Valenti L. Genetic risk scores and personalization of care in fatty liver disease. Curr Opin Pharmacol 2021;61:6-11.
- 106. Israelsen M, Trépo E, Krag A, Stender S. MetALD: genetic factors and clinical outcomes. Semin Liver Dis 2025;45:269-282.
- 107. Chen VL, Kuppa A, Oliveri A, Chen Y, Ponnandy P, Patel PB, et al. Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment. J Clin Invest 2025;135:e186424.
- 108. Nasr P, Wester A, Ekstedt M, Strandberg R, Kechagias S, Shang Y, et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol 2024;22:1048-1057.e2.
- 109. Vaz J, Nasr P, Helander A, Shang Y, Wester A, Strandberg R, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol 2025;83:1011-1022.
- 110. Tavaglione F, Vaz J, Jamialahmadi O, Díaz LA, Ajmera V, Contrano D, et al. The MetALD-ALD prediction index: a phosphatidylethanol-driven biomarker panel for identifying individuals with steatotic liver disease and excessive alcohol use. Gastroenterology 2026;170:1033-1046.
- 111. Tavaglione F, Díaz LA, Ajmera V, Madamba E, Singh S, Bettencourt R, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol 2025;83:1023-1034.
- 112. Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Männistö V, Sammalkorpi H, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of nonalcoholic fatty liver disease. J Hepatol 2022;76:526-535.
- 113. Urias E, Tedesco NR, Oliveri A, Raut C, Speliotes EK, Chen VL. PNPLA3 risk allele association with ALT response to semaglutide treatment. Gastroenterology 2024;166:515-517.e2.
- 114. Boeckmans J, Gatzios A, Schattenberg JM, Koek GH, Rodrigues RM, Vanhaecke T. PNPLA3 I148M and response to treatment for hepatic steatosis: a systematic review. Liver Int 2023;43:975-988.
- 115. Krawczyk M, Jiménez-Agüero R, Alustiza JM, Emparanza JI, Perugorria MJ, Bujanda L, et al. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis 2016;12:1838-1846.
- 116. Eriksson JW, Lundkvist P, Jansson PA, Johansson L, Kvarnström M, Moris L, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018;61:1923-1934.
- 117. Scorletti E, West AL, Bhatia L, Hoile SP, McCormick KG, Burdge GC, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. J Hepatol 2015;63:1476-1483.
- 118. Nobili V, Bedogni G, Donati B, Alisi A, Valenti L. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food 2013;16:957-960.
- 119. Johnson SM, Bao H, McMahon CE, Chen Y, Burr SD, Anderson AM, et al. PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein. Nat Commun 2024;15:4847.
- 120. Barata L, Feitosa MF, Bielak LF, Halligan B, Baldridge AS, Guo X, et al. Insulin resistance exacerbates genetic predisposition to nonalcoholic fatty liver disease in individuals without diabetes. Hepatol Commun 2019;3:894-907.
- 121. Chalasani N, Vilar-Gomez E, Loomba R, Yates KP, Diehl AM, Neuschwander-Tetri BA, et al. PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology 2024;80:1212-1226.
- 122. Tan J, Shi C, Wang G, Zhang L, Li F, Yan G, et al. FTO mediates m6A demethylation of HNF1A and drives hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Biochim Biophys Acta Mol Cell Biol Lipids 2026;1871:159732.
- 123. Tsedendorj Y, Daramjav D, Enkhbat Y, Dondov G, Dashjamts G, Khayankhyarvaa E, et al. Genetic risk of MASLD in Mongolians: role of PNPLA3 and FTO SNPs. Curr Issues Mol Biol 2025;47:605.
- 124. Kilpeläinen TO, Zillikens MC, Stančákova A, Finucane FM, Ried JS, Langenberg C, et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet 2011;43:753-760.
- 125. Truong XT, Lee DH. Hepatic insulin resistance and steatosis in metabolic dysfunction-associated steatotic liver disease: new insights into mechanisms and clinical implications. Diabetes Metab J 2025;49:964-986.
- 126. Mehrdad M, Doaei S, Gholamalizadeh M, Eftekhari MH. The association between FTO genotype with macronutrients and calorie intake in overweight adults. Lipids Health Dis 2020;19:197.
- 127. Chen VL, Du X, Oliveri A, Chen Y, Kuppa A, Halligan BD, et al. Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort. J Hepatol 2024;81:379-388.
- 128. Vilar-Gomez E, Gawrieh S, Vuppalanchi R, Kettler C, Pike F, Samala N, et al. PNPLA3 rs738409, environmental factors and liver-related mortality in the US population. J Hepatol 2025;82:571-581.
- 129. Kim HS, Xiao X, Byun J, Jun G, DeSantis SM, Chen H, et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw Open 2022;5:e2234221.
- 130. Villavicencio EA, Maldonado A, Crocker RM, Guan Y, Stallman C, Garcia DO. Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men. Front Public Health 2022;10:1090101.
- 131. Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol 2022;77:365-376.
- 132. De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L, et al. A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol 2022;20:658-673.
- 133. Chen VL, Oliveri A, Miller MJ, Wijarnpreecha K, Du X, Chen Y, et al. PNPLA3 Genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology 2023;164:966-977.e17.
- 134. Bridi L, Agrawal S, Tesfai K, Madamba E, Bettencourt R, Richards LM, et al. The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. Aliment Pharmacol Ther 2024;60:369-377.
- 135. Kaplan DE, Teerlink CC, Schwantes-An TH, Norden-Krichmar TM, DuVall SL, Morgan TR, et al. Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease. Hepatol Commun 2024;8:e0487.
- 136. Seko Y, Yamaguchi K, Shima T, Iwaki M, Takahashi H, Kawanaka M, et al. The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: a multicentre cohort study. Liver Int 2023;43:2210-2219.
- 137. Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, et al. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis. J Hepatol 2023;78:584-595.
- 138. Thrift AP, Kanwal F, Lim H, Duong H, Liu Y, Singal AG, et al. PNPLA3, obesity, and heavy alcohol use in cirrhosis patients may exert a synergistic increase hepatocellular carcinoma risk. Clin Gastroenterol Hepatol 2024;22:1858-1866.e4.
- 139. Ajmera V, Huang DQ, Chen VL, Reddy KR. Monogenic and polygenic risk in common liver diseases: implications for clinical care. Gastroenterology 2026;171:253-270.
- 140. Fabbrini E, Rady B, Koshkina A, Jeon JY, Ayyar VS, Gargano C, et al. Phase 1 trials of PNPLA3 siRNA in I148M homozygous patients with MAFLD. N Engl J Med 2024;391:475-476.
- 141. Armisen J, Rauschecker M, Sarv J, Liljeblad M, Wernevik L, Niazi M, et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials. J Hepatol 2025;83:31-42.
- 142. Loomba R, Nakajima A, Arrese M, Bugianesi E, Pachori A, Fjellstrom O, et al. GS-003 A PNPLA3 antisense oligonucleotide, AZD, for the treatment of MASH in I148M homozygous participants: results from the phase 2b FORTUNA study. J Hepatology 2026;84:S2-S3.
- 143. Sanyal AJ, Taubel J, Badri P, Bond S, Makarova N, Zhao W, et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol 2025;83:838-848.
- 144. Loomba R, Morgan E, Yousefi K, Li D, Geary R, Bhanot S, et al. Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, doubleblind, placebo-controlled, phase 2 trial. Lancet 2025;406:821-831.
- 145. Sanyal A, Bugianesi E, Chalasani N, Park YS, Tang Y, Perfield JW, et al. Impact of PNPLA3 rs738409 variant on the response to tirzepatide versus placebo for the treatment of non-cirrhotic MASH. Paper presented at: AASLD The Liver Meeting. 2024 Nov 15-19. San Diego, Ca, USA: p. 22.
- 146. Cusi K, Gastaldelli A, Fernandez Lando L, Liu M, Torcello-Gomez A, Rodríguez Á. 759-P: Changes in liver fat in patients with type 2 diabetes by presence of genetic hepatic steatosis in the SURPASS-3 MRI substudy. Diabetes 2023;72(Suppl 1):759-P.
- 147. Chalasani N, Labriola D, Taub R, Anstee Q. Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles. Gastroenterol Hepatol (N Y) 2024;20:16-17.
- 148. Klein JM, Busch JD, Potting C, Baker MJ, Langer T, Schwarz G. The mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane. J Biol Chem 2012;287:42795-42803.
- 149. Kubitza C, Bittner F, Ginsel C, Havemeyer A, Clement B, Scheidig AJ. Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes. Proc Natl Acad Sci U S A 2018;115:11958-11963.
- 150. Fairfield CJ, Drake TM, Pius R, Bretherick AD, Campbell A, Clark DW, et al. Genome-wide association study of NAFLD using electronic health records. Hepatol Commun 2022;6:297-308.
- 151. Emdin CA, Haas ME, Khera AV, Aragam K, Chaffin M, Klarin D, et al. A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet 2020;16:e1008629.
- 152. He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother 2020;132:110851.
- 153. Stickel F, Hampe J. Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk. Lancet Oncol 2022;23:14-16.
- 154. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009;18:4081-4088.
- 155. Adam M, Heikelä H, Sobolewski C, Portius D, Mäki-Jouppila J, Mehmood A, et al. Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice. Faseb j 2018;32:3434-3447.
- 156. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 2006;43:352-361.
- 157. Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R. Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 2004;279:45685-45692.
- 158. Terra ML, Sant’Anna TBF, de Barros JJF, de Araujo NM. Geographic and viral etiology patterns of TERT promoter and CTNNB1 Exon 3 mutations in hepatocellular carcinoma: a comprehensive review. Int J Mol Sci 2025;26:2889.
- 159. Huda N, Kusumanchi P, Jiang Y, Gao H, Thoudam T, Zeng G, et al. Silencing FAF2 mitigates alcohol-induced hepatic steatosis by modulating lipolysis and PCSK9 pathway. Hepatol Commun 2025;9:e0641.
- 160. Burkhardt R, Toh SA, Lagor WR, Birkeland A, Levin M, Li X, et al. Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest 2010;120:4410-4414.
- 161. Smith KR, Wang W, Miller MR, Boucher M, Reynold JE, Daurio NA, et al. GPAT1 deficiency in mice modulates NASH progression in a model-dependent manner. Cell Mol Gastroenterol Hepatol 2024;17:279-291.
- 162. Bathurst IC, Travis J, George PM, Carrell RW. Structural and functional characterization of the abnormal Z alpha 1-antitrypsin isolated from human liver. FEBS Lett 1984;177:179-183.
- 163. Chen VL, Chen Y, Du X, Handelman SK, Speliotes EK. Genetic variants that associate with cirrhosis have pleiotropic effects on human traits. Liver Int 2020;40:405-415.
- 164. Mahdessian H, Taxiarchis A, Popov S, Silveira A, Franco-Cereceda A, Hamsten A, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci U S A 2014;111:8913-8918.
- 165. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352-356.
- 166. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985;26:556-565.
- 167. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010;42:21-23.
- 168. Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, et al. The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One 2011;6:e27087.